Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Homoharringtonine + ADT in Neoadjuvant Prostate Cancer
NCT06834321Phase 2Recruiting
- Start
- Mar 2025
- Primary completion
- Sep 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing Homoharringtonine + ADT with Placebo + ADT (2 arms). Primary endpoint: Pathological Complete Response or Minimal Residual Disease Rate at 4 weeks. Started Mar 2025; status: recruiting.
02
Drugs
homoharringtonine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06834321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834321.